





RealRate

PHARMACEUTICAL 2020

Oncotelic Therapeutics Inc. Rank 113 of 358



The relative strengths and weaknesses of Oncotelic Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Oncotelic Therapeutics Inc. compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 403% points. The greatest weakness of Oncotelic Therapeutics Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 53% points.

The company's Economic Capital Ratio, given in the ranking table, is 147%, being 111% points above the market average of 36%.

Input Variable	Value in 1000 USD
Assets, Current	273
Cost of Goods Sold	0
Intangible Assets	21,987
Liabilities, Current	6,783
Liabilities, Non-Current	0
Other Assets	1,377
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	-2,327
Other Revenues	0
Property and Equipment	48
Research and Development	1,372
Selling, General and Administrative Expense	2,939

Output Variable	Value in 1000 USD
Assets	23,685
Liabilities	6,783
Expenses	4,311
Revenues	0
Stockholders Equity	16,902
Net Income	-6,638
Comprehensive Net Income	-6,638
Economic Capital Ratio	147%